



Metabolism and Metabolic Targeting of Neuroblastoma

Guest Editors:

Dr. Sepideh Aminzadeh-Gohari

Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria

Prof. Dr. Barbara Kofler

Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, Paracelsus Medical University, 5020 Salzburg, Austria

Deadline for manuscript submissions:

closed (30 September 2023)

Message from the Guest Editors

Dear Colleagues,

Neuroblastoma is one of the most common pediatric cancers that remains incurable in about 50% of children in high-risk stages despite aggressive multimodal treatment strategies. Even when patients survive, they usually have a high morbidity due to the side effects of intensive therapies, and are at risk of tumor recurrence.

Alterations in metabolic pathways such as glycolysis, mitochondrial respiration and lipid as well as amino acid metabolism are recognized hallmarks of neuroblastoma that contribute to tumor progression and interact with the tumor microenvironment, influencing the response and resistance to therapies.

Therefore, therapeutics targeting different facets of tumor metabolism are considered new and effective options to improve the efficacy of standard cancer therapies such as chemo-, radio-, and immunotherapy, and to mitigate the side effects of such therapies. This Special Issue of *Metabolites* presents the latest research on metabolism in neuroblastoma and therapeutic options in this area.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale
Civile di Baggiovara, Azienda
Ospedaliero-Universitaria, 41126
Modena, Italy

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Contact Us

Metabolites Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/metabolites
metabolites@mdpi.com
[X@MetabolitesMDPI](https://twitter.com/MetabolitesMDPI)